guest ::
| Home > Publications database > Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma. > print |
| Home > Publications database > Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma. > print |
| 001 | 307575 | ||
| 005 | 20260110120407.0 | ||
| 024 | 7 | _ | |a 10.2967/jnumed.125.270906 |2 doi |
| 024 | 7 | _ | |a pmid:41506801 |2 pmid |
| 024 | 7 | _ | |a 0097-9058 |2 ISSN |
| 024 | 7 | _ | |a 0022-3123 |2 ISSN |
| 024 | 7 | _ | |a 0161-5505 |2 ISSN |
| 024 | 7 | _ | |a 1535-5667 |2 ISSN |
| 024 | 7 | _ | |a 2159-662X |2 ISSN |
| 037 | _ | _ | |a DKFZ-2026-00070 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kessler, Lukas |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma. |
| 260 | _ | _ | |a New York, NY |c 2026 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1767968424_3737039 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #DKTKZFB9# / #NCTZFB26# / epub |
| 520 | _ | _ | |a High expression of fibroblast activation protein (FAP) has been associated with inferior survival in several tumor entities. Novel 68Ga-radiolabeled FAP inhibitors (68Ga-FAPIs) allow noninvasive measurement of FAP, which enables the development of prognostic imaging parameters from 68Ga-FAPI PET/CT. In this study, we compared the prognostic value of 68Ga-FAPI-46 with 18F-FDG PET in a cohort of patients with malignant pleural mesothelioma from the FAPI PET observational trial (NCT04571086). Methods: Between May 2020 and January 2024, 49 patients with suspected or proven malignant mesothelioma were recruited, 39 of whom were eligible for data analysis. All patients underwent 68Ga-FAPI-46 and 18F-FDG PET/CT less than 4 wk apart. Tumor burden was measured semiautomatically, and SUVmax, SUVmean, and volumetric parameters (metabolic tumor volume [MTV], total lesion glycolysis/total lesion fibroblast activation, and total tumor SUV) were calculated. The FAP immunoreactive score (IRS) was calculated for tumor samples from a subset of patients (n = 19). Overall survival and progression-free survival were assessed per revised mRECIST (version 1.1). Survival analyses were performed with univariate and multivariate Cox regression and with Kaplan-Meier curves for clinical and imaging parameters, stratified by median. Results: Univariate analysis showed significant survival differences for all volumetric parameters for 68Ga-FAPI-46 and 18F-FDG (e.g., 68Ga-FAPI-46 MTV, 262 d vs. 737 d; P = 0.008 vs. 18F-FDG MTV, 336 d vs. 760 d; P = 0.012). Multivariate analysis revealed that MTV was an independent prognostic marker for 68Ga-FAPI-46 (hazard ratio, 4.44; 95% CI, 1.20-16.43; P = 0.025) and 18F-FDG (hazard ratio, 7.01; 95% CI, 1.29-38.2; P = 0.024). Kaplan-Meier analysis of the FAP IRS found that a higher IRS was associated with poorer survival (438 d with an IRS of 0-3 vs. 1,076 d with an IRS of 4-12; P = 0.04), but no significant difference was observed in univariate and multivariate analyses. Conclusion: In this modest exploratory cohort of patients with malignant pleural mesothelioma, MTV determined by 68Ga-FAPI-46 and 18F-FDG PET/CT had similar prognostic value, and high MTV was an independent risk factor. 68Ga-FAPI-46 not only complements a diagnostic work-up but also provides prognostic value and could offer alternative theranostic strategies for these patients. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a FAPI |2 Other |
| 650 | _ | 7 | |a cancer imaging |2 Other |
| 650 | _ | 7 | |a fibroblast activation protein |2 Other |
| 650 | _ | 7 | |a mesothelioma |2 Other |
| 650 | _ | 7 | |a theranostic |2 Other |
| 700 | 1 | _ | |a Schwaning, Felix |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Metzenmacher, Martin |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Pabst, Kim M |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Opitz, Marcel |b 4 |
| 700 | 1 | _ | |a Wiesweg, Marcel |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Aigner, Clemens |b 6 |
| 700 | 1 | _ | |a Ploenes, Till |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Boeloekbas, Servet |b 8 |
| 700 | 1 | _ | |a Doerr, Fabian |b 9 |
| 700 | 1 | _ | |a Stuschke, Martin |b 10 |
| 700 | 1 | _ | |a Umutlu, Lale |b 11 |
| 700 | 1 | _ | |a Nader, Michael |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Theegarten, Dirk |b 13 |
| 700 | 1 | _ | |a Eberhardt, Wilfried E |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Schuler, Martin |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Herrmann, Ken |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Fendler, Wolfgang P |0 P:(DE-HGF)0 |b 17 |
| 700 | 1 | _ | |a Kersting, David |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Hautzel, Hubertus |0 P:(DE-HGF)0 |b 19 |
| 773 | _ | _ | |a 10.2967/jnumed.125.270906 |g p. jnumed.125.270906 - |0 PERI:(DE-600)2040222-3 |p nn |t Journal of nuclear medicine |v nn |y 2026 |x 0097-9058 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:307575 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2026 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NUCL MED : 2022 |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-01 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-01 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NUCL MED : 2022 |d 2025-01-01 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)WT01-20160331 |k WT01 |l Koordinierungsstelle NCT West |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)DD04-20160331 |k DD04 |l Koordinierungsstelle NCT Dresden |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)WT01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)DD04-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|